Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.43M 2.23M 2.08M 3.94M 264M 4M 26.6M 10.4M 130M 10.41M 10.18M 448M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.68M 7.98M 7.43M 14.1M 945M 14.31M 95.22M 37.22M 464M 37.26M 36.45M 1.6B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 29/02/2012
Investor Relations Contact - 30/04/2014
Corporate Officer/Principal 77 29/11/2022
Director TitleAgeSince
Chairman 61 29/02/2012
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.87%+8.57%+54.24%+147.40% 27.28B
Weighted average by Cap. +2.46%+6.47%+58.32%+136.98%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.96 0.11 0.7 0.27 3.42 0.27 0.27 11.8 0.14 0.12 0.11 0.1 0.19 12.89 0.2 1.3 0.51 6.33 0.51 0.5 21.85
Net income -3.1M -2.72M -2.5M -2.33M -4.41M -296M -4.48M -29.78M -11.64M -145M -11.65M -11.4M -501M -18.47M -16.16M -14.85M -13.84M -26.24M -1.76B -26.64M -177M -69.28M -864M -69.34M -67.85M -2.98B
Net Debt 7.1M 6.2M 5.7M 5.31M 10.08M 675M 10.23M 68.06M 26.61M 332M 26.63M 26.06M 1.15B 7.15M 6.26M 5.75M 5.36M 10.16M 681M 10.31M 68.62M 26.82M 335M 26.85M 26.27M 1.15B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-